quizartinib-resistant FLT3 mutants don't bind quizartinib

Stable Identifier
R-HSA-9702618
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
quizartinib-resistant FLT3 mutants don't bind quizartinib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following FLT3 mutants are resistant to quizartinib (also known as AC220):
FLT3 A627P (Williams et al, 2013)
FLT3 F691L (Albers et al, 2013; Baker et al, 2013; Galanis et al, 2014; Smith et al, 2015; Williams et al, 2013)
FLT3 Y842C (partial: Williams et al, 2013)
FLT3 Y842H (partial: Albers et al, 2013)
FLT3 N676D (partial: Albers et al, 2013)
FLT3 D835A (Nguyen et al, 2017)
FLT3 D835F (Galanis et al, 2014; Smith et al, 2012; 2013;2015)
FLT3 D835H (Baker et al, 2013; Galanis et al, 2014; Smith et al, 2015)
FLT3 D835V (Galanis et al, 2014; Smith et al, 2012; 2013;2015)
FLT3 D835Y (Galanis et al, 2014; Moore et al, 2012: Nguyen et al, 2017; Smith et al, 2012; 2013;2015)
Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Nguyen, B, Williams, AB, Young, DJ, Ma, H, Li, L, Levis, M, Brown, P, Small, D

Oncotarget 2017
23392356 The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

Albers, C, Leischner, H, Verbeek, M, Yu, C, Illert, AL, Peschel, C, von Bubnoff, N, Duyster, J

Leukemia 2013
22354205 Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

Moore, AS, Faisal, A, Gonzalez de Castro, D, Bavetsias, V, Sun, C, Atrash, B, Valenti, M, de Haven Brandon, A, Avery, S, Mair, D, Mirabella, F, Swansbury, J, Pearson, AD, Workman, P, Blagg, J, Raynaud, FI, Eccles, SA, Linardopoulos, S

Leukemia 2012
23969938 Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia

Baker, SD, Zimmerman, EI, Wang, YD, Orwick, S, Zatechka, DS, Buaboonnam, J, Neale, GA, Olsen, SR, Enemark, EJ, Shurtleff, S, Rubnitz, JE, Mullighan, CG, Inaba, H

Clin. Cancer Res. 2013
24227820 Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Galanis, A, Ma, H, Rajkhowa, T, Ramachandran, A, Small, D, Cortes, J, Levis, M

Blood 2014
Participants
Input
Participates
as an event of
Normal reaction
FLT3 binds type II TKI (Homo sapiens)
Functional status

Loss of function of quizartinib-resistant FLT3 mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!